Indivior’s restructuring plan is taking shape with initial headcount reductions.
The first phase of the company’s “Indivior Action Agenda,” which looks to “generate momentum” and lay the groundwork for the rest of the three-pronged plan, is ongoing through the end of 2025. Along with growing its opi--d use disorder treatment Sublocade in the U.S. and pinpointing the “actions and investments” necessary to further penetrate the long-acting injectable market, the agenda includes actions to simplify the organization by “eliminating all non-essential activities,” the company explained in a Tuesday SEC filing.
https://www.fiercepharma.com/pharma/indivior-slims-headcount-weighs-opvee-divesture-phase-1-multi-year-restructuring-plan?_gl=1*rzswv7*_gcl_au*MTIzNTEwMTM3OS4xNzU2Mjg0MzA2*_ga*MTMzNDQxOTAwNy4xNzU2Mjg0MjM5*_ga_KG49J84SR4*czE3NTY0NjMxNDMkbzQkZzEkdDE3NTY0NjMyODEkajU4JGwwJGgw